Award
National Cancer Institute 5R01CA235800-05
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
Recipient
Not Specified
Award Amount
$547,212.00
Ceiling
$547,212.00
Awarded
September 01, 2023
Identifier
5R01CA235800-05
Award for clinical development and testing of Rhenium nanoliposomes for glioblastoma treatment, including safety trials and drug distribution modeling.
Description
The project aims to test the maximum tolerable dose and safety profile of Rhenium nanoliposomes in patients with recurrent glioma. It includes developing and validating a mathematical model to predict the distribution of RNL186. The project involves preclinical studies in rats and dogs, followed by clinical trials, focusing on safety, efficacy, and modeling of drug distribution for glioblastoma, a highly aggressive brain tumor.